Skip to content

Earnings yield at other companies

Baxter International logo
Baxter InternationalBAX
-12.7%-19.1pp
PTH
Pelthos Therapeutics Inc.PTHS
-73.2%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
72.9%+61.3pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-5.1%-1.7pp
RFL
Rafael Holdings, Inc.RFL
-31.4%-3.8pp
Opko Health logo
Opko HealthOPK
-24.6%-29.5pp

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+138%
Enterprise value$90.91M+207%
P/S2.3×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Calculated from Cumberland Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's earnings yield?
Cumberland Pharmaceuticals (CPIX) reported earnings yield of -15.2% in Q1 2026.
How has Cumberland Pharmaceuticals's earnings yield changed year-over-year?
Cumberland Pharmaceuticals's earnings yield decreased by 173.9% year-over-year, from -5.5% to -15.2%.
What is the long-term trend for Cumberland Pharmaceuticals's earnings yield?
Over 5 years (2020 to 2025), Cumberland Pharmaceuticals's earnings yield has grown at a -8.8% compound annual growth rate (CAGR), from -7.6% to -4.8%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.